Kenai Therapeutics

About Kenai Therapeutics

Kenai Therapeutics is a clinical-stage biotechnology company focused on developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines to treat neurological conditions. The company aims to deliver disease-modifying and potentially curative treatments that go beyond symptom management, with programs targeting neurodegenerative diseases such as Parkinson’s disease. Kenai emphasizes neuron replacement therapies with promising preclinical results and a pipeline designed to restore quality of life for patients. Headquartered in the United States, Kenai progresses through clinical development to advance next-generation approaches for neurological disorders.